Ignite Creation Date:
2024-05-11 @ 8:31 AM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06405724
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-05-08
First Post:
2024-05-05
Brief Title:
Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Surgical Pain After Video-Assisted Thoracoscopic Surgery
Sponsor:
Feng Gao
Organization:
Tongji Hospital
Study Overview
Official Title:
Comparison of the Ultrasound-guided Paravertebral Nerve Block With Liposomal Bupivacaine Versus Ropivacaine for Post-Surgical Pain After Video-Assisted Thoracoscopic SurgeryA Single-Center Prospective Randomized and Controlled Trial
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Prospective randomized and controlled trial to compare the postoperative pain management of paravertebral nerve block with liposomal bupivacaine to ropivacaine in patients undergoing elective thoracoscopic surgery
Detailed Description:
The objective of this study is to validate the analgesic efficacy of liposomal bupivacaine LB compared with ropivacaine when injected for paravertebral nerve block PVB for video-assisted thoracoscopic surgery VATS
We hypothesize that LB will be superior to ropivacaine in terms of postoperative pain control following VATS The primary outcome of this study will be NRS pain scores for resting pain and NRS pain scores for cough pain 24 hours following surgery Secondary outcomes will include pain scores over the first 120 hours following surgery opioid consumption opioid-related adverse events block-related adverse events time of first getting out of bed catheter indwelling time postoperative hospitalization time patient satisfaction and chronic pain at 1 3 and 6 months after surgery
We hypothesize that LB will be superior to ropivacaine in terms of postoperative pain control following VATS The primary outcome of this study will be NRS pain scores for resting pain and NRS pain scores for cough pain 24 hours following surgery Secondary outcomes will include pain scores over the first 120 hours following surgery opioid consumption opioid-related adverse events block-related adverse events time of first getting out of bed catheter indwelling time postoperative hospitalization time patient satisfaction and chronic pain at 1 3 and 6 months after surgery
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None